PRIMACYT
Cell Culture Technology

HHCP Human Hepatocytes Cryopreserved Plateable **Cell Specification – Certificate of Analysis (CoA)**	
Lot cPHH270824459	Batch Release: September 26, 2025

Donor data	
Species: Human	Gender: female Age: 63 years Smoker: 15 cigarettes per day
Diagnosis: Hepatocellular carcinoma Medical History: Porphyria, hypothyroidism, COPD	Therapy: Hemihepatectomy right Medication: Levothyroxine, Citalopram Serology: negative for HBV, HCV, HIV 1/2

Cryopreservation and Thawing	
Cryopreservation: Date: Aug 27, 2024 Amount per vial: 5.0 x 10^6 cells	**Thawing:** n=2 Post-thaw viability: 97.1 ± 0.5 % Post-thaw yield per vial: 3.1 ± 0.3 x 10^6 cells Recovery: 63 % **Only one spin required. No washing step.**

2D culture	
Phase contrast on day 1 after thawing (24well plate)	Phase contrast on day 3 after thawing (24well plate)
	
Recommended seeding density on collagen-coated plates: 24well plate – 400,000 cells/well Culture in Human Hepatocyte Maintenance Medium (HHMM)	

E-mail: info@primacyt.de, Tel.: +49 (0) 385-3993-600, Fax: +49 (0) 385-3993-602

PRIMACYT
Cell Culture Technology

Suspension culture
Viability test on orbital shaker (Eppendorf Thermomixer C, 1000 rpm at 37 °C with 0.5 x 10^6 cells in 0.5 mL HPM-Cryo):

Time (h)	0	1	2	3	4	5
Viability (%)	97.1	93.0	88.6	89.5	89.6	87.3

Note: Yield, viability, recovery and activity assays were performed at PRIMACYT using PRIMACYT's manual for thawing, plating and culture of primary cryopreserved hepatocytes.

Note for thawing process: Only one spin at 100 x g, 10 min., 20 °C is required. No washing step needed.

Store at -150 °C or in the vapour phase of LN_2

This product should be considered as potential biohazard. Only intended for *in vitro* use.

Issued by: A. Ullrich	Verified by: T. Krimmling